1-(cyclopentylsulfonyl)-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole | 1226781-75-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯并吡唑类
• 英文名称: 1-(cyclopentylsulfonyl)-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole
• 英文别名: 1-cyclopentylsulfonyl-5,6-dihydro-4H-pyrrolo[3,4-c]pyrazole
• CAS: 1226781-75-4
• 化学式: C₁₀H₁₅N₃O₂S
• 分子量: 241.314
• InChiKey: IBFRZIPSHPZMSY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.1
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.7
• 拓扑面积：
  72.4
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  N-[(2R,3S)-2-(2,5-二氟苯基)四氢-5-氧代-2H-吡喃-3-基]氨基甲酸叔丁酯 、 1-(cyclopentylsulfonyl)-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole 在 decaborane 作用下， 以 甲醇 为溶剂， 反应 18.5h， 生成 tert-butyl {(2R,3S,5R)-2-(2,5-difluorophenyl)-5-[1-(cyclopentylsulfonyl)-4,6-dihydropyrrolo[3,4-c]pyrazol-5(4H)-yl]tetrahydro-2H-pyran-3-yl}carbamate
  参考文献：
  名称：

  AMINOTETRAHYDROPYRANS AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES

  摘要：

  本发明涉及结构式I的新型取代氨基四氢吡喃衍生物，它们是二肽基肽酶-IV酶的抑制剂，可用于治疗或预防二肽基肽酶-IV酶参与的疾病，如糖尿病，特别是2型糖尿病。该发明还涉及包含这些化合物的药物组合物，以及这些化合物和组合物在预防或治疗二肽基肽酶-IV酶参与的疾病中的用途。

  公开号：

  US20100120863A1
• 作为产物：
  描述：

  tert-butyl 1-(cyclopentylsulfonyl)-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxylate 在 三氟乙酸 、 ammonium hydroxide 作用下， 以 二氯甲烷 、 甲醇 为溶剂， 反应 2.0h， 生成 1-(cyclopentylsulfonyl)-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole
  参考文献：
  名称：

  AMINOTETRAHYDROPYRANS AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES

  摘要：

  本发明涉及结构式I的新型取代氨基四氢吡喃衍生物，它们是二肽基肽酶-IV酶的抑制剂，可用于治疗或预防二肽基肽酶-IV酶参与的疾病，如糖尿病，特别是2型糖尿病。该发明还涉及包含这些化合物的药物组合物，以及这些化合物和组合物在预防或治疗二肽基肽酶-IV酶参与的疾病中的用途。

  公开号：

  US20100120863A1

文献信息

• [EN] AMINOTETRAHYDROPYRANS AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES<br/>[FR] AMINOTÉTRAHYDROPYRANES EN TANT QU'INHIBITEURS DE DIPEPTIDYLE PEPTIDASE-IV POUR LE TRAITEMENT OU LA PRÉVENTION DU DIABÈTE
  申请人：MERCK SHARP & DOHME

  公开号：WO2010056708A1

  公开（公告）日：2010-05-20

  The present invention is directed to novel substituted aminotetrahydropyrans of structural formula I which are inhibitors of the dipeptidyl peptidase-IV enzyme and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly Type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.

  本发明涉及结构式I的新型取代氨基四氢吡喃衍生物，其是二肽基肽酶IV酶的抑制剂，并且在治疗或预防二肽基肽酶IV酶参与的疾病，如糖尿病和特别是2型糖尿病方面非常有用。本发明还涉及包含这些化合物的制药组合物，以及在预防或治疗二肽基肽酶IV酶参与的这些疾病方面使用这些化合物和组合物。
• AMINOTETRAHYDROPYRANS AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OF DIABETES
  申请人：Merck Sharp & Dohme Corp.

  公开号：US20150126443A1

  公开（公告）日：2015-05-07

  The present invention is directed to novel substituted aminotetrahydropyrans of structural formula I which are inhibitors of the dipeptidyl peptidase-IV enzyme and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly Type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.

  本发明涉及结构式I的新型取代氨基四氢吡喃衍生物，其为二肽基肽酶IV酶的抑制剂，并且在治疗或预防二肽基肽酶IV酶参与的疾病，如糖尿病和特别是2型糖尿病方面具有用处。本发明还涉及包含这些化合物的制药组合物以及在预防或治疗二肽基肽酶IV酶参与的这类疾病中使用这些化合物和组合物。
• Combination drugs comprising aminotetrahydropyrans as Dipeptidyl Peptidase-IV Inhibitors for the Treatment or Prevention of Diabetes
  申请人：Merck Sharp & Dohme Corp.

  公开号：EP2676960A1

  公开（公告）日：2013-12-25

  The present invention is directed to a combination comprising a compound of structural formula I or a pharmaceutically acceptable salt thereof and a biguanide; wherein the variables are as defined in the specification.Compouds (I) are inhibtors of the enzyme dipeptidyl peptidase IV (dpp4-inhibitors) and may be used in the reatment of diabetes.

  本发明涉及一种组合物，该组合物包含结构式 I 的化合物或其药学上可接受的盐和双胍；其中变量如说明书中所定义。
• Structure–activity-relationship of amide and sulfonamide analogs of omarigliptin
  作者：Ping Chen、Dennis Feng、Xiaoxia Qian、James Apgar、Robert Wilkening、Jeffrey T. Kuethe、Ying-Duo Gao、Giovanna Scapin、Jason Cox、George Doss、George Eiermann、Huaibing He、Xiaohua Li、Kathryn A. Lyons、Joseph Metzger、Aleksandr Petrov、Joseph K. Wu、Shiyao Xu、Ann E. Weber、Youwei Yan、Ranabir Sinha Roy、Tesfaye Biftu

  DOI：10.1016/j.bmcl.2015.10.070

  日期：2015.12

  A series of novel substituted-[(3R)-amino-2-(2,5-difluorophenyl)]tetrahydro-2H-pyran analogs have been prepared and evaluated as potent, selective and orally active DPP-4 inhibitors. These efforts lead to the discovery of a long acting DPP-4 inhibitor, omarigliptin (MK-3102), which recently completed phase III clinical development and has been approved in Japan. (C) 2015 Elsevier Ltd. All rights reserved.
• Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
  申请人：Merck Sharp & Dohme Corp.

  公开号：EP2358717A1

  公开（公告）日：2011-08-24